JP2014527532A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014527532A5 JP2014527532A5 JP2014526261A JP2014526261A JP2014527532A5 JP 2014527532 A5 JP2014527532 A5 JP 2014527532A5 JP 2014526261 A JP2014526261 A JP 2014526261A JP 2014526261 A JP2014526261 A JP 2014526261A JP 2014527532 A5 JP2014527532 A5 JP 2014527532A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- compound according
- hydrogen
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 150000002148 esters Chemical class 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 claims 4
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- OTGQIQQTPXJQRG-UHFFFAOYSA-N N-(octadecanoyl)ethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCO OTGQIQQTPXJQRG-UHFFFAOYSA-N 0.000 claims 2
- 125000003158 alcohol group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229950007031 palmidrol Drugs 0.000 claims 2
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- -1 tetrahydropyran-4-yl Chemical group 0.000 claims 2
- 206010011224 Cough Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 201000010927 Mucositis Diseases 0.000 claims 1
- 201000009053 Neurodermatitis Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 210000005223 peripheral sensory neuron Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161525636P | 2011-08-19 | 2011-08-19 | |
| US61/525,636 | 2011-08-19 | ||
| PCT/US2012/051478 WO2013028570A2 (en) | 2011-08-19 | 2012-08-17 | Meta-substituted biphenyl peripherally restricted faah inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014527532A JP2014527532A (ja) | 2014-10-16 |
| JP2014527532A5 true JP2014527532A5 (OSRAM) | 2015-10-01 |
| JP6092870B2 JP6092870B2 (ja) | 2017-03-08 |
Family
ID=47747054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014526261A Active JP6092870B2 (ja) | 2011-08-19 | 2012-08-17 | メタ置換ビフェニル末梢に限局されたｆａａｈ阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9745255B2 (OSRAM) |
| EP (1) | EP2744778B1 (OSRAM) |
| JP (1) | JP6092870B2 (OSRAM) |
| KR (1) | KR102079404B1 (OSRAM) |
| CN (1) | CN104203906B (OSRAM) |
| AU (1) | AU2012299060B2 (OSRAM) |
| BR (1) | BR112014003886B1 (OSRAM) |
| CA (1) | CA2844812C (OSRAM) |
| DK (1) | DK2744778T3 (OSRAM) |
| ES (1) | ES2708723T3 (OSRAM) |
| MX (1) | MX354772B (OSRAM) |
| WO (1) | WO2013028570A2 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100485727B1 (ko) * | 2004-06-24 | 2005-04-27 | 주식회사 바이오리더스 | 폴리감마글루탐산-비타민 복합체 및 그 용도 |
| AU2012299060B2 (en) | 2011-08-19 | 2017-06-01 | Fondazione Istituto Italiano Di Tecnologia | Meta-substituted biphenyl peripherally restricted FAAH inhibitors |
| WO2014023325A1 (en) * | 2012-08-06 | 2014-02-13 | Fondazione Istituto Italiano Di Tecnologia | Multitarget faah and cox inhibitors and therapeutical uses thereof |
| WO2015157313A1 (en) | 2014-04-07 | 2015-10-15 | The Regents Of The University Of California | Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments |
| CN108348468A (zh) * | 2015-08-11 | 2018-07-31 | Eyesiu医疗股份有限公司 | 具有生物活性亲脂性化合物的聚乙二醇化脂质纳米粒 |
| ES2910787T3 (es) * | 2016-05-12 | 2022-05-13 | Univ Michigan Regents | Inhibidores de ASH1L y métodos de tratamiento con los mismos |
| SG10201802129QA (en) | 2017-07-05 | 2019-02-27 | Frimline Private Ltd | A pharmaceutical composition for neuropathic pain |
| US10702487B2 (en) | 2017-08-19 | 2020-07-07 | Frimline Private Limited | Pharmaceutical composition for prevention of diet induced obesity |
| SG10201807034XA (en) | 2017-09-05 | 2019-04-29 | Frimline Private Ltd | A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease |
| GB201802326D0 (en) | 2018-02-13 | 2018-03-28 | Ucl Business Plc | Gene therapy |
| WO2019173394A1 (en) | 2018-03-05 | 2019-09-12 | Wylder Nation Foundation | Compositions and methods for activating signaling through the cb1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin |
| US20220112225A1 (en) * | 2019-01-10 | 2022-04-14 | Travecta Therapeutics Pte. Ltd. | Anandamide compounds |
| US20230313196A1 (en) * | 2020-07-23 | 2023-10-05 | John Mansell | Compositions and methods for treating pain and anxiety disorders |
| CN120965462A (zh) * | 2025-10-17 | 2025-11-18 | 四川奥邦古得药业有限公司 | 用于生产3,5-二醚戊苯的方法及其在制备3,5-二羟基戊苯中的应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4325889A (en) | 1978-08-04 | 1982-04-20 | Bayer Aktiengesellschaft | Process for the preparation of 1-amino-8-naphthol-3,6-disulphonic acid (H-acid) |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4511503A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US5541061A (en) | 1992-04-29 | 1996-07-30 | Affymax Technologies N.V. | Methods for screening factorial chemical libraries |
| EP0604289B1 (fr) | 1992-12-17 | 1997-09-24 | Valeo Systemes D'essuyage | Procédé et dispositif d'alimentation d'un moteur électrique d'entrainement d'un bras d'essuie-glace de véhicule automobile |
| US5576220A (en) | 1993-02-19 | 1996-11-19 | Arris Pharmaceutical Corporation | Thin film HPMP matrix systems and methods for constructing and displaying ligands |
| US6271015B1 (en) | 1995-06-12 | 2001-08-07 | The Scripps Research Institute | Fatty-acid amide hydrolase |
| CA2206192A1 (en) | 1996-06-13 | 1997-12-13 | F. Hoffmann-La Roche Ag | Modulation of lc132 (opioid-like) receptor function |
| AU731672B2 (en) | 1996-12-02 | 2001-04-05 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating bipolar disorders |
| GB9701453D0 (en) | 1997-01-24 | 1997-03-12 | Leo Pharm Prod Ltd | Aminobenzophenones |
| FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| TW492882B (en) | 1997-11-28 | 2002-07-01 | Caleb Pharmaceuticals Inc | Cholinergic antagonist plaster composition |
| NZ506465A (en) | 1998-02-26 | 2003-08-29 | Akzo Nobel Nv | Derivatives of azetidine and pyrrolidine |
| US6348498B1 (en) | 1998-05-29 | 2002-02-19 | Neurosciences Research Foundation, Inc. | Control of pain with endogenous cannabinoids |
| US7897598B2 (en) | 1998-06-09 | 2011-03-01 | Alexandros Makriyannis | Inhibitors of the anandamide transporter |
| US20030134894A1 (en) | 1999-04-07 | 2003-07-17 | Daniele Piomelli | Methods of treating mental diseases, inflammation and pain |
| US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
| JP4488350B2 (ja) | 2002-05-16 | 2010-06-23 | セプラコール インク． | 哺乳類アナンダミド輸送体を阻害するアミン、およびその使用方法 |
| FR2842808B1 (fr) | 2002-07-25 | 2004-09-10 | Sod Conseils Rech Applic | Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques |
| JP4515911B2 (ja) * | 2002-10-07 | 2010-08-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アナンダミド加水分解の遮断による不安の調節 |
| FR2850377B1 (fr) | 2003-01-23 | 2009-02-20 | Sanofi Synthelabo | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866888B1 (fr) | 2004-02-26 | 2006-05-05 | Sanofi Synthelabo | Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique |
| US20070155707A1 (en) | 2005-12-29 | 2007-07-05 | Kadmus Pharmaceuticals, Inc. | Ionizable inhibitors of fatty acid amide hydrolase |
| US9316633B2 (en) | 2006-11-16 | 2016-04-19 | The Regents Of The University Of California | Methods for identifying inhibitors of solute transporters |
| US20080119549A1 (en) * | 2006-11-20 | 2008-05-22 | N.V. Organon | Metabolically-stabilized inhibitors of fatty acid amide hydrolase |
| TW200948805A (en) | 2008-03-07 | 2009-12-01 | Sigma Tau Ind Farmaceuti | Enol carbamate derivatives as modulators of fatty acid amide hydrolase |
| PL2488486T3 (pl) | 2009-10-13 | 2020-01-31 | Ligand Pharmaceuticals Inc. | Małocząsteczkowe związki mimetyczne hematopoetycznego czynnika wzrostu i ich zastosowania |
| CN103153946B (zh) | 2010-07-28 | 2015-11-25 | 加利福尼亚大学董事会 | 外周限制性 faah 抑制剂 |
| WO2012167133A2 (en) | 2011-06-01 | 2012-12-06 | The Regents Of The University Of California | Inhibitors of anandamide transport and their therapeutic uses |
| AU2012299060B2 (en) | 2011-08-19 | 2017-06-01 | Fondazione Istituto Italiano Di Tecnologia | Meta-substituted biphenyl peripherally restricted FAAH inhibitors |
| WO2015157313A1 (en) | 2014-04-07 | 2015-10-15 | The Regents Of The University Of California | Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments |
-
2012
- 2012-08-17 AU AU2012299060A patent/AU2012299060B2/en active Active
- 2012-08-17 EP EP12826376.1A patent/EP2744778B1/en active Active
- 2012-08-17 CA CA2844812A patent/CA2844812C/en active Active
- 2012-08-17 WO PCT/US2012/051478 patent/WO2013028570A2/en not_active Ceased
- 2012-08-17 ES ES12826376T patent/ES2708723T3/es active Active
- 2012-08-17 JP JP2014526261A patent/JP6092870B2/ja active Active
- 2012-08-17 DK DK12826376.1T patent/DK2744778T3/en active
- 2012-08-17 KR KR1020147007303A patent/KR102079404B1/ko active Active
- 2012-08-17 BR BR112014003886-4A patent/BR112014003886B1/pt active IP Right Grant
- 2012-08-17 CN CN201280051448.5A patent/CN104203906B/zh active Active
- 2012-08-17 MX MX2014001966A patent/MX354772B/es active IP Right Grant
-
2014
- 2014-02-18 US US14/183,073 patent/US9745255B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014527532A5 (OSRAM) | ||
| RU2013108944A (ru) | Ингибиторы faah периферически-ограниченного действия | |
| RU2013112807A (ru) | Композиция для доставки активных агентов в желудок | |
| EP4338805A3 (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| NZ734905A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| RU2018111327A (ru) | Способ ингибирования всасывания и/или повышения выведения липидов с использованием d-псикозы | |
| NZ619076A (en) | Isoxazolines as inhibitors of fatty acid amide hydrolase | |
| EP3363797A8 (en) | Oral dosage form of apoptosis signal-regulating kinase inhibitors | |
| HRP20160203T1 (hr) | Pripravci koji sadrže 15-hepe i postupci njihove upotrebe | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| WO2008154083A3 (en) | Compounds, compositions and methods for the treatment of synucleinopathies | |
| RU2014136394A (ru) | Морфолиноалкилфумаратные соединения, фармацевтические композиции и способы применения | |
| WO2011116139A3 (en) | Improved pharmaceutical compositions comprising cck- 8 and methods of delivery | |
| RU2017112149A (ru) | Комбинация омега-3 жирной кислоты и SGLT-2 ингибитора для лечения болезней печени | |
| CO6150156A2 (es) | Esteres de dha y su utilizacion en el tratamiento y la prevencion de enfermedades cardiovasculares | |
| JP2016512227A5 (OSRAM) | ||
| WO2011089126A3 (en) | Novel retigabine composition | |
| JP2014210824A5 (OSRAM) | ||
| EA201300539A1 (ru) | Твердая композиция для приема внутрь (варианты), способ терапевтической или нетерапевтической профилактики желудочно-кишечных расстройств или поддержания здорового состояния желудочно-кишечного тракта с ее помощью (варианты) и упаковка, ее содержащая | |
| UA106907C2 (uk) | Стабілізована фармацевтична композиція | |
| RU2015104097A (ru) | Соединения мочевины и их применение в качестве ингибиторов ферментов | |
| JP2011515470A5 (OSRAM) | ||
| EA201270653A1 (ru) | Антагонист dpи его применение | |
| WO2011143271A3 (en) | Therapeutic liposomes and methods for producing and using the same | |
| JP2014509637A5 (OSRAM) |